Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT)

European Journal of Haematology

Volumn 90, Issue 3, 2013, Pages 177-186

  Le Bourgeois, Amandine ^a   Lestang, Elsa ^a   Guillaume, Thierry ^a   Delaunay, Jacques ^a   Ayari, Sameh ^a   Blin, Nicolas ^a   Clavert, Aline ^a   Tessoulin, Benoit ^a   Dubruille, Viviane ^a   Mahe, Beatrice ^a   Roland, Virginie ^a   Gastinne, Thomas ^a   Le Gouill, Steven ^a   Moreau, Philippe ^a   Mohty, Mohamad ^a,b   Planche, Lucie ^a   Chevallier, Patrice ^a,b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Allo stem cells transplantations; antithymocyte globulin; FB2; Hematopoietic recovery; Immune reconstitution; reduced intensity conditioning

Indexed keywords

BUSULFAN; CYCLOSPORIN A; CYTOKINE; FLUDARABINE; GROWTH FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; DISEASE FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE STATUS; IMMUNOSTIMULATION; LEUKOCYTE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOCYTE; MORTALITY; NEUTROPHIL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY;

ADULT; AGED; ANTILYMPHOCYTE SERUM; BUSULFAN; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, INNATE; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 84873987765     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12049     Document Type: Article

References (36)

1. Passweg JR, Baldomero H, Gratwohl A, et al. The EBMT activity survey: 1990-2012. Bone Marrow Transplant 2012;47:906-23.
2. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009;15:1628-33.
3. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukaemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005;19:2304-12.
4. Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010;116:4439-43.
5. Jimenez M, Ercilla G, Martinez C. Immune reconstitution alter allogeneic stem cell transplantation with reduced-intensity conditioning regimens. Leukemia 2007;21:1628-37.
6. Michallet M, Le Q, Mohty M, et al. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Exp Hematol 2008;5:535-44.
7. Blaise D, Mohty M, Milpied N, et al. Allogeneic stem cell transplantation from matched related donor in patients over the age of 55 years: a prospective multicenter phase II study of a reduced intensity conditioning associating fludarabin-IV busulfan and thymoglobulin. Blood, ASH Annual Meeting Abstracts, 2011;21:195.
8. Blaise D, Tabrizi R, Boher JM, et al. Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. Cancer 2012. doi:10.1002/cncr.27786. Epub ahead of print Aug 14.
9. Lioure B, Bene MC, Pigneux A, et al. Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. Blood 2012;119:2943-8.
10. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with letal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood 1998;91:756-63.
11. Cahu X, Mohty M, Faucher C, et al. Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens. Bone Marrow Transplant 2008;42:689-91.
12. Takama H, Tanaka H, Nakashima D, et al. Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2006;4:345-51.
13. Mohty M, de Lavallade H, Faucher C, et al. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004;6:527-30.
14. Brissot E, Chevallier P, Guillaume T, et al. Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors. Bone Marrow Transplant 2009;4:786-8.
15. Rondón G, Saliba RM, Khouri I, et al. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant 2008;14:859-66.
16. Schichman SA, Suess P, Vertino AM, et al. Comparison of short tandem repeat and variable number tandem repeat genetic markers for quantitative determination of allogeneic bone marrow transplant engraftment. Bone Marrow Transplant 2002;29:243-8.
17. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706.
18. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18:295-304.
19. Shulman H, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-17.
20. Chevallier P, Szydlo RM, Blaise D, et al. Reduced-intensity conditioning prior to allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. Biol Blood Marrow Transplant 2012;18:289-94.
21. Shimoni A, Nagler A. Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still need. Best Pract Res Clin Haematol 2011;24:369-79.
22. Chevallier P, Labopin M, Buchholz S, et al. Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. Eur J Haematol 2012;89:214-9.
23. Perez-Simon JA, Caballero D, Diez-Campelo M, et al. Chimerism and minimal residual disease monitoring alter reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002;16:1423-31.
24. Mohty M, Avinens O, Faucher C, et al. Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica 2007;92:1004-6.
25. Holtan SG, Hogan WJ, Elliott MA, et al. CD34+ cell dose and establishment of full donor chimerism at day+100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies. Bone Marrow Transplant 2010;45:1699-703.
26. Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008;26:577-84.
27. Larosa F, Marmier C, Robinet E, et al. Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation. Bone Marrow Transplant 2005;35:859-68.
28. Dodero A, Carrabba M, Milani R, et al. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp Hematol 2005;33:920-7.
29. Castermans E, Baron F, Willems E, et al. Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning. Haematologica 2008;93:240-7.
30. Baron F, Fillet G, Beguin Y. Erythropoiesis after nonmyeloablative stem-cell transplantation is not impaired by inadequate erythropoietin production as observed after conventional allogeneic transplantation. Transplantation 2002;74:1692-6.
31. Ivanov V, Faucher C, Mohty M, et al. Early administration of recombinant erythropoietin improves haemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation. Bone Marrow Transplant 2005;36:901-6.
32. Mohty M, Faucher C, Blaise D. Graft-versus-host-disease and granulocyte colony-stimulating factor administration after allogeneic stem cell transplantation. Leukemia 2005;19:500-3.
33. Trivedi M, Martinez S, Corringham S, et al. Optimal use of G-CSF administration after hematopoietic SCT. Bone Marrow Transplant 2009;43:895-908.
34. Anderlini P, Przepiorka D, Champlin R, et al. Biological and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood 1998;88:2819-25.
35. Gyger M, Stuart RK, Perreault C. Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor. Bone Marrow Transplant 2000;26:1-16.
36. Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma 2000;38:221-34.